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We previously reported that the clone JK34 was cross-reactive for dengue virus types 1, 2, 3, and 4 and
recognized NS3 (I. Kurane, M. A. Brinton, A. L. Samson, and F. A. Ennis, J. Virol. 65:1823-1828, 1991). In
the present experiments, we defined the epitope at the amino acid level, with 93 15-mer overlapping peptides
which cover the entire NS3. A peptide 4 which contains amino acids 251 to 265 of NS3 sensitized the autologous
B lymphoblastoid cell line (LCL) to the lysis by JK34. The smallest peptide recognized by JK34 was a 10-mer
peptide which contains amino acids 255 to 264 (EIVDLMCHAT). A monoclonal antibody to EIIA-DP inhibited
the lysis of epitope peptide-pulsed autologous LCL by JK34. Genotypic typing revealed that the HLA-DP of this
donor is DPA1*01, DPB1*0201, which is serologically defined as HLA-DPw2. JK34 lysed peptide 4-pulsed
allogeneic LCL which carried HLA-DPw2. These results indicate that HLA-DPw2 is the restriction allele for
recognition of this epitope by JK34.
Dengue virus infections are a serious cause of morbidity
and mortality in many areas of the world: southeast and
south Asia, Central and South America, and the Caribbean
(9, 11). Dengue virus infection can be asymptomatic or cause
two forms of disease (8). Dengue fever is a self-limited
febrile disease. In some situations, patients infected with
dengue virus leak plasma into interstitial spaces, resulting in
hypovolemia and sometimes circulatory collapse. This se-
vere life-threatening syndrome is termed dengue hemor-
rhagic fever (DHF).
Development of dengue virus vaccines is a potential
method for preventing dengue virus infections; however, the
epidemiological observations have shown that DHF is ob-
served much more commonly in secondary dengue virus
infections than in primary infections (1, 9). These observa-
tions raise the possibility that dengue virus vaccine may
induce immune responses which could lead to the immuno-
pathology of DHF. Dengue virus vaccines should induce
protective immune responses but should not induce immu-
nity which may increase the risk of DHF during future
dengue virus infections. Although protective immune mech-
anisms against dengue viruses are not understood, it is
believed that serotype-specific neutralizing antibodies can
prevent dengue virus infections and that dengue virus-
specific cytotoxic T lymphocytes (CTL) contribute to recov-
ery from infection. Therefore, experimental subunit vac-
cines should include neutralizing B-cell epitopes and
dominant CTL and helper T-cell epitopes.
We have reported that the NS3 protein was recognized by
the majority of CD4+ CTL clones established from a dengue
virus-infected individual (14). Identification and character-
ization at the amino acid levels of these CD4+ CTL epitopes
will provide useful information for the future development of
dengue vaccines. In this paper, we define an epitope on NS3
* Corresponding author.
recognized by a dengue virus serotype-cross-reactive CD4+
CD8- CTL clone, JK34, with overlapping synthetic pep-
tides.
Dengue virus type 1, Hawaii strain; type 2, New Guinea C
strain; type 3, CH53489 strain; and type 4, 814669 strain;
yellow fever virus (17D strain); and West Nile virus (ElOl
strain) were used. Dengue virus, yellow fever virus, and
West Nile virus antigens were prepared by using dengue
virus-infected Vero cells as previously reported (16). Syn-
thetic peptides of the NS3 protein of dengue virus type 4,
814669 strain (17), were synthesized with the RaMPS system
(DuPont, Boston, Mass.) as previously reported (6, 23). The
peptides consist of 15 amino acids (aa) which overlapped
each other by 7 to 10 residues.
Cytotoxic assays were done as previously reported (14).
In cytotoxic assays using synthetic peptides, 10 cells in 0.1
ml were incubated with peptide in 0.05 ml for 30 min, and
effector cells in 0.05 ml were then added to each well. After
incubation at 37°C for 6 h, the supernatant fluid was col-
lected from each well and counted in an automatic gamma
counter. The percent specific 51Cr release was calculated by
the following formula: 100 x (counts per minute of experi-
mental release - counts per minute of spontaneous release)/
(counts per minute of maximal release - counts per minute
of spontaneous release). Concentrations of the peptide
which induce 50% maximum lysis were calculated on the
basis of the dose-response curves with peptide at concentra-
tions from 25 p,M to 2.5 x 10'6 j,M, and the percent specific
lysis of dengue virus type 3 antigen-cultured target cells was
considered as the maximum lysis in the experiment. The
10th International Histocompatibility Workshop lympho-
blastoid cell lines (LCL) (10w9023, -9011, -9029, -9038,
-9022, -9052, and -9077) (American Society for Histocompat-
ibility and Immunogenetics, Lenexa, Kans.) were used in
HILA-DP restriction experiments.
The HLA-DPA1 and -DPB1 genotype of the donor was
established by polymerase chain reaction amplification of
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FIG. 1. Recognition of a peptide 4 (aa 251 to 265) by a dengue
serotype-cross-reactive CD4+ CTL clone, JK34. A total of 103
autologous LCL were incubated with 8 x 103 JK34 cells (effector/
target ratio = 8:1) for 6 h in the presence of peptides at 20 FM.
Dengue 4 Ag, dengue virus type 4 antigen.
the first domain of DPA1 and DPB1 genes and hybridization
with sequence-specific oligonucleotide probes as previously
described (19, 20).
The establishment and partial characterization of the JK34
clone have been already reported (14). Briefly, JK34 was
established from the peripheral blood mononuclear cells of a
donor who had been infected with dengue type 3 virus
(CH53489) 1 year earlier, with a limiting dilution technique.
JK34 has a CD3+ CD4+ CD8- phenotype and has dengue
virus-specific cytotoxic activity. JK34 is cross-reactive for
dengue virus types 1, 2, 3, and 4 but not for yellow fever
virus or West Nile virus.
TABLE 2. HLA-DP-restricted lysis of the target cells by JK34a
% Specific 51Cr release
Monoclonal
antibody addedb Dengue virus Peptide None
type 3 antigen 4
None 76 62 0
Anti-HLA-DP 2 8 NDC
Anti-HLA-DQ 83 57 ND
Anti-HLA-DR 90 52 ND
Anti-HLA class I 87 66 ND
a A total of 2.5 x 103 autologous LCL were incubated with 2.5 x 104 JK34
cells (effector/target ratio = 10:1) for 6 h in the presence of monoclonal
antibodies at a final dilution of 1:80. The peptide at 25 ,uM was included in the
cytotoxic assay.
b B7/21, S3/4, OKIal (Ortho Diagnostic Systems, Inc., Raritan, N.J.), and
W6/32 (Accurate Biochemical Co., Westbury, N.J.) were used as anti-HLA-
DP, anti-HLA-DQ, anti-HLA-DR, and anti-HILA class I, respectively.
I ND, not determined.
After demonstrating that clone JK34 recognized the NS3
protein (14), we attempted to determine the epitope recog-
nized by JK34, with 93 15-mer overlapping peptides which
covered the entire NS3 protein. Only peptide 4 which
contains aa residues 251 to 265 (HTGREIVDLMCHATF)
sensitized autologous LCL to the lysis by JK34 (Fig. 1).
None of the other peptides sensitized autologous LCL to the
lysis by JK34 (data not shown). To further delineate the
smallest peptide recognized by this clone, we synthesized N-
and C-terminal truncations of peptide 4 as shown in Table 1.
Peptides 4a, 4b, 4c, 4d, 4f, and 4k sensitized autologous LCL
to the lysis by JK34. These results indicate that the smallest
peptide recognized by JK34 is located on aa 255 to 264,
which have the amino acid sequence of EIVDLMCHAT.
HLA restriction in the recognition of the epitope by JK34
was first examined with monoclonal antibodies to HLA
molecules (Table 2). A monoclonal antibody to HLA-DP
inhibited the lysis of peptide 4-pulsed target cells and dengue
virus type 3 antigen-cultured target cells by JK34, but
monoclonal antibodies to HLA-DQ, HLA-DR, and HLA
class I did not. This result confirmed that recognition of the
epitope by JK34 is HLA-DP restricted as previously re-
ported (14). In order to determine HLA-DP allelic restric-
TABLE 1. Determination of the core epitope recognized by JK34 with truncated synthetic peptides
Aminoacids % Specific ~~~~~~~~~~~~~~Peptideconcn (pM)Peptide on NS3 Amino acid sequence 5'Cr releasea lept ib uM
4 251-265 HTGREIVDLMCHATF 50 2.5
4a 252-265 TGREIVDLMCHATF 44 4.4
4b 253-265 GREIVDLMLCHATF 40 8.3
4c 254-265 BEIVDLMCHATF 50 3.5
4d 255-265 EIVDLMCHATF 34 11
4e 256-265 IVDLMCHATF 11 >25
4f 251-264 HTGREIVDLMCHAT 26 23
4g 251-263 HTGREIVDLMCHA 9 >25
4h 251-262 HTGREIVDLMCH 2 >25
4i 251-261 HTGREIVDLMC 1 >25
4j 251-260 HTGREIVDLM 0 >25
4k 255-264 EIVDLMCHAT 28 17
41 255-263 EIVDLMCHA 0 >25
4m 256-264 IVDLMCHAT 3 >25
None 0
a Percent specific 51Cr release at the peptide concentration of 25 jI.M. Effector/target ratio was 14:1. The assay was for 6 h.b Peptide concentrations which induce 50% maximum lysis were calculated on the basis of dose-response curves as stated in the text. Percent specific lysis of
dengue virus type 3 antigen-cultured autologous LCL was 51%.
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TABLE 3. HLA-DPw2-restricted lysis of peptide 4-pulsed
allogeneic LCL by JK34'
TargetHLA-DP ~~Genotype % SpecificTarget DLA-DP G notpe51Cr releaseb
Autologous w2 01 0201 89
9023 wl 02 0101 4
9011 w2, w4 01 0201, 0401 40
9029 w2 01 0201 20
9038 w2 01 0201 40
9022 w3 01 0301 4
9052 w4 01 0401 5
9077 w5 NAC NA 0
a A total of 103 autologous or allogeneic LCL were incubated with 1.2 x 104
JK34 cells (effector/target ratio = 12:1) for 6 h in the presence of peptide 4 at
25 ,M.
b Percent specific 5'Cr release of autologous LCL without peptide 4 was 0.
c NA denotes data not available.
tion, the HLA-DP alleles of this donor were defined by
oligonucleotide typing. The results revealed that this donor
is homozygous for DPA1*01, DPB1*0201, which is serolog-
ically defined as HLA-DPw2. HLA-DP-typed allogeneic
LCL were then used in CTL assays. Allogeneic LCL which
express HLA-DPw2 and were pulsed with peptide 4 were
lysed by JK34, but allogeneic LCL which express other
HLA-DP alleles were not (Table 3). These results indicate
that recognition of this epitope by JK34 is restricted by
HLA-DPw2.
The NS3 genes of dengue virus types 1, 2, 3, and 4 have
been sequenced (7, 13, 17, 18). The epitope determined in
this study is completely conserved among dengue virus
types 1, 2, 3, and 4, which is compatible with the dengue
serotype cross-reactivity of this clone. This clone did not
recognize yellow fever virus or West Nile virus. Yellow
fever virus has three substitutions, I to V at aa 256, V to I at
aa 257, and L to A at aa 259 (21), and West Nile virus has one
substitution, L to V at aa 259 (2, 24).
The epitopes recognized by HLA-DP-restricted, human
CD4+ T-cell clones have only been defined for a few viruses.
HLA-DPw4-restricted epitopes on hepatitis B virus, rabies
virus, and human immunodeficiency virus type 1 were
identified (3, 4, 10). The result reported in the present paper
is, however, the first definition of the HLA-DPw2-restricted
epitope recognized by human CD4+ T cells. The core of the
HLA-DPw4-restricted epitopes on hepatitis B virus and
human immunodeficiency virus type 1 has been reported to
be 10 and 12 aa residues, respectively (3, 10), whereas the
smallest peptide recognized by HLA-DPw2-restricted T-cell
clone JK34 contains 10 aa residues. There is a stretch of 5 aa
residues which is conserved among those three HLA-DPw4-
restricted epitopes, and this area of homology contains a
motif of Arg-X-Leu, where X is a hydrophobic amino acid
(10). The HLA-DPw2-restricted epitope on dengue virus has
no homology with those HLA-DPw4-restricted epitopes.
Some naturally processed peptides bound to major histo-
compatibility complex class II molecules have been isolated
from human and murine cells and been sequenced (5, 12, 22).
Chicz et al. have reported that peptides isolated from HLA-
DR1 were 13 to 25 aa long and that these peptides displayed
a high degree of heterogeneity both in length and the site of
terminal truncation (5). Rudensky et al. showed that pep-
tides isolated from I-Ab and I-Eb were 13 to 17 aa long and
discussed not finding simple patterns of amino acids in
peptides (22). Hunt et al. reported that peptides isolated
from I-Ad were 16 to 18 aa long and contained a 6-residue
binding motif (12). Although we have determined that the
clone recognizes a peptide that is 10 aa long, the naturally
processed peptide which is recognized by JK34 would be
longer. Isolation of the naturally processed epitope from
dengue virus-infected autologous cells will be important to
perform in the future.
The role of dengue virus-specific CD4+ CTIL in dengue
virus infections is poorly understood. It is likely that CD4+
CTL contribute to prevention of infection and recovery from
dengue virus infection by helping the generation of neutral-
izing antibodies and CD8+ CTL and by lysing dengue
virus-infected HLA class II-bearing cells. It is also possible
that these CD4+ CTL contribute to the pathogenesis of DHF
by lymphokine production and cytotoxic activities (15). If
CD4+ CTL do contribute to prevention and recovery, the
epitopes recognized by these dengue serotype-cross-reactive
clones should be included in the subunit vaccines. It is
therefore important to map the epitopes recognized by other
dengue virus-specific T-cell clones and determine the HLA
restriction of these clones. This information will be useful in
the development of safe and effective dengue virus vaccines
in the future.
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